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Objective: To evaluate the neuroprotective effects of the organic components of scallop
shells (scallop shell extract) on memory impairment and locomotor activity induced by
scopolamine or 5-methyl-10,11-dihydro-5H-dibenzo (a,d) cyclohepten-5,10-imine (MK801).
Methods: Effect of the scallop shell extract on memory impairment and locomotor ac-
tivity was investigated using the Y-maze test, the Morris water maze test, and the open
ﬁeld test.
Results: Scallop shell extract signiﬁcantly reduced scopolamine-induced short-term
memory impairment and partially reduced scopolamine-induced spatial memory
impairment in the Morris water maze test. Scallop shell extract suppressed scopolamine-
induced elevation of acetylcholine esterase activity in the cerebral cortex. Treatment with
scallop shell extract reversed the increase in locomotor activity induced by scopolamine.
Scallop shell extract also suppressed the increase in locomotor activity induced by
MK801.
Conclusions: Our results provide initial evidence that scallop shell extract reduces
scopolamine-induced memory impairment and suppresses MK-801-induced
hyperlocomotion.1. Introduction
Scallops are one of the major marine products in Hokkaido,
Japan. Approximately 200000 tons of scallop shells per year is
generated as industrial waste. Although scallop shells are efﬁ-
ciently used as antibacterial agents or as a material for desulfur-
ization, additional modes of utilization are desired. Towards this
aim, we have previously investigated the in vitro activities of
scallop shell extract and found several biological activities [1–3].
Memory impairment is caused not only by aging or stress,
but also by neurodegenerative diseases such as Alzheimer's
disease. In Alzheimer's disease, a deﬁcit of acetylcholine due to
a reduction in hippocampal cholinergic neuronal activity is one
of the most important causes of memory impairment [4,5].
Scopolamine is a muscarinic acetylcholine receptor antagonist
that induces learning and memory impairment through thecholinergic neuronal system. This effect has been proposed to
mimic the cognitive and behavioral deﬁcits seen during aging
and in Alzheimer's disease. Therefore, scopolamine has been
widely used to induce cognitive deﬁcits in animal models of
neurologic disease [6–8].
Schizophrenia is a severe neuropsychiatric disorder charac-
terized by a core of psychiatric symptoms, including positive,
negative, and cognitive symptoms [9]. MK801 is a selective N-
methyl-D-aspartate (NMDA) receptor antagonist that induces
amnesic and psychomotor effects. In rodents, MK801 induces
hyperlocomotion characterized by agitation and stereotyped
behavior, both of which are thought to be aspects of
schizophrenia. Therefore, MK801 treatment has been used as
an animal model of schizophrenia [10–12].
While scallop shells are composed of the CaCO3 polymorph of
the prismatic layer, pearl oyster shells consist of two types of
CaCO3 polymorphs, the prismatic layer and the nacreous layer.
Since the nacreous layer (pearl) has long been thought to be
effective in maintaining a stable emotional state in traditional
Chinese medicine, we considered the possibility that scallop shell
extract might also affect brain function. In this study, we evaluated
the effects of scallop shell extract on scopolamine-inducedmemory
impairment and MK801-induced locomotor activity.icle under the CC BY-NC-ND license (http://
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2.1. Materials
Scopolamine and MK801 were purchased from Sigma (St.
Louis, MO, USA). Scallops of the species Patinopecten yes-
soensis, harvested from Mutsu Bay, Aomori, Japan, were pur-
chased and their shells separated.
2.2. Preparation of scallop shell extract
Scallop shell extract was prepared as described previously [1].
Brieﬂy, scallop shells were crushed and ground to a powder. For
complete decalciﬁcation, the shell powder (approximately
200 g) was dialyzed against 1 L of 5% acetic acid. This was
followed by exhaustive dialysis against 1 L of deionized water
to remove the acetic acid. After dialysis, the decalciﬁed
solution was concentrated by lyophilization, and the sample
was resuspended in deionized water. The water-soluble frac-
tion was used as scallop shell extract.
2.3. Animals
Male Wistar rats (4-week-old) were purchased from CLEA
(Tokyo, Japan). They were housed individually in a room at
22 C. The husbandry of the rats was in accordance with the
Guidelines of Experimental Animal Care issued by the Ofﬁce of
the Prime Minister of Japan and the Muroran Institute of
Technology. The rats were used in experiments after an accli-
matization period.
2.4. Short-term memory and locomotor activity
evaluation in the Y-maze test
The Y-maze is a three-arm maze with equal angles between
the arms, each 30 cm in length and 20 cm in height. The rat was
placed in the center of the maze, and the sequence and number
of arm entries were recorded for each rat for 10 min. Any
combination of three sequential entries in which the rat entered
all three arms (e.g., ABC, CAB, or BCA, but not ABB), was
recorded as a spontaneous alternation. The percentage of spon-
taneous alternation behavior was calculated according to the
following equation: alternation (%) = [(number of alternations)/
(total arm entries − 2)] × 100. Spontaneous alternation is
believed to reﬂect spatial working memory, which is a form of
short-term memory. The total number of arm entries reﬂects
locomotor activity.
The rats were tested in groups of ﬁve or six. One hour before
the test, scallop shell extract or phosphate buffered saline (PBS)
was administered intraperitoneally (10, 50, or 75 mg/kg). The
dosage was selected based on the results in the preliminary
experiment. After 30 min, scopolamine (1 mg/kg) or MK801
(0.35 mg/kg) was administered. The test was started 30 min after
the scopolamine or MK801 treatment. The control group
received PBS alone.
2.5. Spatial memory evaluation in the Morris water
maze test
A round pool (170 cm in diameter) was ﬁlled with water
(22 C) containing black ink. A circular platform (15 cm indiameter) was placed in the pool and submerged 5 cm below the
water surface. Three visual cues were positioned at different
points along the perimeter of the pool. In the experiment, the rats
were given an acquisition trial on each of the seven consecutive
days. The rat was placed in the water near the edge of the pool
and allowed to search for the platform for 120 s. If the rat did not
reach the platform within 120 s, it was placed on the platform for
10 s. The escape latency time (i.e., the amount of time it took the
rat to locate the platform) of was recorded at each acquisition
trial. One hour before the trial, the rats were injected intraperi-
toneally with PBS or scallop shell extract (10 mg/kg). After
30 min, scopolamine (1 mg/kg) was administered intraperito-
neally. All trials were started 30 min after the scopolamine
treatment. The control group received PBS alone.
2.6. The open-ﬁeld test
The open-ﬁeld chamber consisted of a metal cylinder 35 cm
in diameter and 50 cm in height. The ﬂoor was divided into eight
equal areas by intersecting lines drawn on the ﬂoor. Locomotor
activity was measured as the number of times all four legs of the
rat crossed one of the lines. One hour before the test, scallop
shell extract or PBS was administered intraperitoneally (75 mg/
kg). After 30 min, MK801 (0.35 mg/kg) was administered, and
the test was started 30 min after the MK801 treatment. The
control group received PBS alone. The movements of the rat
were recorded for 10 min by a video camera.
2.7. The acetylcholine esterase activity assay
Rats used in the Y-maze test were sacriﬁced. The cerebral
cortex was dissected and homogenized in PBS at 4 C to pro-
duce a 20% (w/v) homogenate. The homogenate was centri-
fuged at 12000 ×g for 15 min, and the supernatant (cortical
extract) was used for the measurement of acetylcholine esterase
activity. Acetylcholine esterase activity was measured using a
modiﬁed method of Ellman et al. [13]. Brieﬂy, 2.6 mL of cortical
extract was diluted in PBS, mixed with 0.1 mL of 10 mM 5,50-
dithiobis-2-nitrobenzoate (DTNB), and incubated at 37 C for
5 min. The enzymatic reaction was started by adding 20 mL of
75 mM acetylcholine iodide, and the absorbance at 412 nm was
measured for 30 min. To quantify the acetylcholine esterase
inhibitory activity of scallop shell extract, the measurements
were performed in the presence of various concentrations of
scallop shell extract in a control cortical extract.
2.8. Statistical analysis
Each experiment was performed at least two times. The data
were expressed as the mean and the standard error of mean
(SEM). The data were analyzed using one-way analysis of
variance (one-way ANOVA) followed by Turkey's multiple-
comparison test or Student's t-test.
3. Results
3.1. Effect of scallop shell extract on scopolamine-
induced memory impairment
The effect of scallop shell extract on scopolamine-induced
short-term memory impairment was assessed by studying
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The scopolamine-treated group showed signiﬁcantly decreased
spontaneous alternation compared to the control group (by
approximately 20%). However, the decrease was reversed by
treatment with scallop shell extract at both 10 mg/kg and 50 mg/
kg, showing that scallop shell extract could protect from
scopolamine-induced short-term memory impairment. Scopol-
amine increased the number of arm entries approximately 1.8-
fold. Treatment with scallop shell extract at 50 mg/kg signiﬁ-
cantly suppressed the increase. However, treatment with scallop
shell extract alone did not affect either spontaneous alternation
or the number of arm entries. These results show that scallop
shell extract can reduce scopolamine-induced short-term mem-
ory impairment and suppress the scopolamine-induced increase
of locomotor activity.
3.2. Effect of scallop shell extract on scopolamine-
induced spatial memory impairment
The effect of scallop shell extract on scopolamine-induced
spatial memory impairment was examined in the Morris water
maze test (Figure 2). The control group rapidly learned the
location of the platform, and the mean escape latency time
started to decrease on day 3 of training. The scopolamine-treated
group showed a delayed escape latency time compared with the
control group on days 3–5. Treatment with scallop shell extract
resulted in a partial rescue of the scopolamine-induced delay in
escape latency time on days 3 and 4, although signiﬁcant dif-
ference was not observed. This result suggests that scallop shell
extract reduce scopolamine-induced spatial memory impairment.Figure 1. Effects of scallop shell extract on scopolamine-induced memory im
administered sequentially before the test, and spontaneous alternation percentag
extract alone (10 mg/kg) was administered 30 min before the test, and spontane
determined. The data for ﬁve rats were combined; the bars show the standard er
analysis of variance (ANOVA) with Turkey's test,*: P < 0.05.3.3. Effect of scallop shell extract on acetylcholine
esterase activity
Acetylcholine esterase inhibitors are known to affect
scopolamine-induced memory impairment [14,15]. Scopolamine-
treated rats showed signiﬁcantly increased acetylcholine esterase
activity in the cortex compared to the control group (Figure 3).
Treatment with scallop shell extract signiﬁcantly suppressed the
increase in scopolamine-induced acetylcholine esterase activity.
However, scallop shell extract alone did not inhibit acetylcholine
esterase activity in vitro.
3.4. Effect of scallop shell extract on MK801-induced
locomotor activity
Scallop shell extract reversed the scopolamine-induced in-
crease in locomotor activity (Figure 1). MK801 treatment is
known to induce hyperlocomotion [10,11]. We therefore
examined the effect of scallop shell extract on MK801-
induced locomotor activity in the Y-maze test (Figure 4).
Although MK801 treatment did not signiﬁcantly lower sponta-
neous alternation under our experimental conditions, it did in-
crease the number of arm entries approximately two-fold.
Scallop shell extract suppressed the increase in MK801-induced
locomotor activity to the control level. To conﬁrm this result, we
investigated the effect of scallop shell extract on MK801-
induced locomotor activity in the open-ﬁeld test (Figure 5).
MK801-treated rats showed a remarkable increase in locomotor
activity compared to the control group. This increase was
signiﬁcantly diminished by the administration of scallop shellpairment in the Y-maze test. Scallop shell extract and scopolamine were
e (a) and the number of total arm entries (b) were determined. Scallop shell
ous alternation percentage (c) and the number of total arm entries (d) were
rors of mean (SEM). Statistical signiﬁcance was determined using one-way
Figure 2. Effect of scallop shell extract on scopolamine-induced memory impairment in the Morris-water maze test. Scallop shell extract and scopolamine
were administered sequentially before the test. The escape latencies during training days were measured in: (a) the control group (B) and the scopolamine-
treated group (C); (b) the scopolamine-treated group (C) and the scopolamine and scallop-shell-extract-treated group (▵). The data for six rats were
combined; the bars show the standard errors of mean (SEM). Statistical signiﬁcance was determined using a Student's t-test, *P < 0.05.
Figure 3. Effect of scallop shell extract on acetylcholine esterase activity. (a) Scallop shell extract (10 mg/kg) and scopolamine were administered
sequentially. The cerebral cortices of rats were used to measure acetylcholine esterase activity. The activity shown is per mg of cerebral cortical mass. (b)
Acetylcholine esterase activity was measured in the presence or absence of scallop shell extract. The data for ﬁve rats were combined; the bars show the
standard errors of mean (SEM). Statistical signiﬁcance was determined using one-way analysis of variance ANOVA with Turkey's test, *P < 0.05.
Figure 4. The effects of the scallop shell extract on MK801-induced locomotor activity in Y-maze test. Scallop shell extract and MK801 were administered
sequentially before the test, and spontaneous alternation percentage (a) and the number of total arm entries (b) were determined. The data of ﬁve rats were
combined; the bars show the standard errors of mean (SEM). Statistical signiﬁcance was determined by one-way ANOVA with Turkey's test, *P < 0.05.
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Figure 5. Effect of scallop shell extract on MK801-induced locomotor
activity in the open-ﬁeld test. Scallop shell extract was administered 1 h
before the Y-maze test. MK801 was administered 30 min before the test.
The data for ﬁve rats were combined; the bars show the standard errors of
mean (SEM). Statistical signiﬁcance was determined using one-way anal-
ysis of variance (ANOVA) with Turkey's test, *P < 0.05.
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press scopolamine and MK801-induced locomotor activity.
4. Discussion
In the present study, scallop shell extract prevented
scopolamine-induced memory impairment in the Y-maze and
the Morris water maze tests. An acetylcholine deﬁcit due to
degeneration of the cholinergic nervous system is known to be
one of the most important causes of memory impairment [4,5].
Scopolamine causes memory impairment by interfering with
acetylcholine function at the synapse and partly by increasing
acetylcholine esterase activity in the cortex and the
hippocampus [8]. Scallop shell extract signiﬁcantly suppressed
the scopolamine-induced increase in acetylcholine esterase ac-
tivity in the cortex while unable to inhibit acetylcholine esterase
activity in vitro. This result suggests that scallop shell extract
ameliorates short-term memory loss through a rescue of the
acetylcholine system.
MK801 treatment has been reported to induce memory
impairment in some studies [16,17]. In this study, we could not
observe a signiﬁcant difference in spontaneous alternation
between the control group and the MK801-treated group. This
discrepancy may be due to our using a higher MK801 dose
(0.35 mg/kg) compared to the doses previously used in studies of
memory impairment (0.075–0.1 mg/kg) [16,17]. Further research is
necessary to elucidate the effects of scallop shell extract onmemory
impairment induced by NMDA receptor antagonists.
MK801-induced hyperlocomotion is considered to be an ani-
mal model of the positive symptoms of schizophrenia [10–12].
MK801 induces hyperlocomotion partly by activating the
dopamine neurons in the prefrontal cortex and the hippocampus
[18,19]. On the other hand, scopolamine acts by blocking the
muscarinic acetylcholine receptors on the cholinergic neurons,
thereby disinhibiting these neurons and enabling them to activate
dopamine neurons [20]. Scallop shell extract suppressed the
increase in locomotor activity in response to scopolamine and
MK801. These results suggest that scallop shell extract may alter
dopaminergic neurotransmission.
Recently Zhang et al. showed that administration of pearl
conchiolin protein reduced locomotor activity through down-regulation of 5-hydroxytryptamine (5-HT) and up-regulation of
g-aminobutyric acid (GABA) in the brain [21]. Scallop shell
extract also affect 5-HT3 and GABA neurotransmitter levels. It
is interesting that components in pearl (nacre) and scallop shells
affect brain function.
To date, the bioactive substance in scallop shell extract re-
mains unknown. Attempts to identify the substance and its
mechanisms of action are ongoing. Our results provide initial
evidence that scallop shell extract reduces scopolamine-induced
memory impairment and suppresses MK-801-induced
hyperlocomotion.
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